Research Analysts Set Expectations for CADL Q3 Earnings

Key Points

• HC Wainwright lowered its Q3 2026 EPS forecast for Candel Therapeutics to a loss of $0.35 per share from $0.25, while maintaining a Buy rating and $23 price target.
• Candel reported a quarterly loss of $0.52 per share, missing the $0.24 consensus estimate by $0.28 and underscoring continued cash-burn and execution risks.
• Analyst sentiment remains generally positive, with seven Buy ratings, two Holds and one Sell; the stock has an average rating of Moderate Buy and an average price target of $19.29.

Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Stock analysts at HC Wainwright reduced their Q3 2026 earnings per share estimates for shares of Candel Therapeutics in a research report issued on Thursday, August 13th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($0.35) per share for the quarter, down from their prior estimate of ($0.25). HC Wainwright currently has a "Buy" rating and a $23.00 target price on the stock. The consensus estimate for Candel Therapeutics' current full-year earnings is ($1.03) per share. HC Wainwright also issued estimates for Candel Therapeutics' Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($0.19) EPS and FY2030 earnings at $2.07 EPS.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.28).

A number of other research firms have also commented on CADL. Bank of America upped their price objective on shares of Candel Therapeutics from $9.00 to $12.00 and gave the company a "neutral" rating in a research note on Friday. Wall Street Zen downgraded shares of Candel Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday. Zacks Research upgraded shares of Candel Therapeutics from a "strong sell" rating to a "hold" rating in a report on Friday, May 15th. Cantor Fitzgerald began coverage on shares of Candel Therapeutics in a report on Monday, April 20th. They set an "overweight" rating on the stock. Finally, Stifel Nicolaus assumed coverage on shares of Candel Therapeutics in a research report on Monday, July 13th. They issued a "buy" rating and a $22.00 price target for the company. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Candel Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $19.29.

Candel Therapeutics Stock Performance

Shares of NASDAQ CADL opened at $11.72 on Monday. The business has a fifty day simple moving average of $9.68 and a 200-day simple moving average of $7.41. The company has a market cap of $896.81 million, a price-to-earnings ratio of -8.31 and a beta of -0.51. Candel Therapeutics has a 12 month low of $4.35 and a 12 month high of $11.95. The company has a quick ratio of 16.09, a current ratio of 16.09 and a debt-to-equity ratio of 0.38.

Hedge Funds Weigh In On Candel Therapeutics

Large investors have recently made changes to their positions in the business. Moneta Group Investment Advisors LLC grew its position in Candel Therapeutics by 4.9% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 42,517 shares of the company's stock valued at $240,000 after purchasing an additional 2,000 shares in the last quarter. Invesco Ltd. lifted its position in Candel Therapeutics by 29.0% in the 4th quarter. Invesco Ltd. now owns 15,039 shares of the company's stock worth $85,000 after buying an additional 3,380 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in Candel Therapeutics by 12.6% in the 1st quarter. Janney Montgomery Scott LLC now owns 30,472 shares of the company's stock worth $149,000 after buying an additional 3,400 shares in the last quarter. MetLife Investment Management LLC boosted its stake in shares of Candel Therapeutics by 25.5% during the 4th quarter. MetLife Investment Management LLC now owns 19,443 shares of the company's stock valued at $110,000 after buying an additional 3,955 shares during the period. Finally, BNP Paribas Financial Markets boosted its stake in shares of Candel Therapeutics by 128.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company's stock valued at $40,000 after buying an additional 4,439 shares during the period. Institutional investors and hedge funds own 13.93% of the company's stock.

Insider Buying and Selling at Candel Therapeutics

In related news, insider Francesca Barone sold 23,447 shares of the company's stock in a transaction on Monday, June 29th. The stock was sold at an average price of $10.06, for a total transaction of $235,876.82. Following the transaction, the insider directly owned 77,362 shares of the company's stock, valued at approximately $778,261.72. The trade was a 23.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CTO Seshu Tyagarajan sold 7,000 shares of the stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $10.02, for a total value of $70,140.00. Following the completion of the sale, the chief technology officer directly owned 83,865 shares of the company's stock, valued at approximately $840,327.30. This represents a 7.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 14.30% of the stock is currently owned by insiders.

More Candel Therapeutics News

Here are the key news stories impacting Candel Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $23 price target, implying substantial potential upside from recent trading levels. The firm’s outlook reflects expectations for future earnings growth and progress in Candel’s pipeline. HC Wainwright reaffirms Buy rating and price target
• Positive Sentiment: Management highlighted “meaningful execution” toward a biologics license application (BLA) submission in the fourth quarter. Candel is targeting its first commercial product in 2027, making regulatory progress a key catalyst for the stock. CADL rises as biotech targets 2027 commercial launch
• Neutral Sentiment: Bank of America raised its price target from $9 to $12 but maintained a Neutral rating. The revised target is close to the recent share price, suggesting the analyst sees limited near-term upside despite the higher valuation estimate. Bank of America raises CADL price target
• Negative Sentiment: Candel reported a second-quarter loss of $0.52 per share, substantially worse than the $0.27 consensus estimate. The earnings miss highlights continued cash-burn and execution risk for the clinical-stage biotechnology company. Candel second-quarter earnings release
• Negative Sentiment: HC Wainwright modestly reduced its FY2028 and FY2029 EPS estimates to $0.69 and $1.41, respectively. Although the firm retained its Buy rating and $23 target, the estimate cuts indicate slightly lower expectations for Candel’s long-term profitability.

About Candel Therapeutics

Candel Therapeutics NASDAQ: CADL is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company's lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel's pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source